Ghana's National Vaccine Institute (NVI) is actively searching for investors to build the nation's capacity for local vaccine production by the year 2030. The institute requires significant funding to ensure Ghana can produce its own vaccines and avoid relying on external sources.
This push for local manufacturing is driven by the impending end of funding from the global vaccine alliance, GAVI. By 2030, Ghana is projected to need approximately $50 million annually to procure vaccines. The NVI is therefore looking to engage strategic investors, including the Ghana Exim Bank, Afreximbank, and the International Finance Corporation (IFC). These institutions are expected to provide financial backing to local manufacturers.
This effort aligns with a broader national goal of achieving health sovereignty, a concept championed by President John Dramani Mahama. The shift towards local production is a response to the vulnerability of relying on donor funding for essential medical supplies. Recent data shows Ghana paid $15 million in counterpart funding to GAVI this year, highlighting the growing national investment in vaccine procurement. The move aims to redirect significant annual expenditures towards strengthening the domestic economy and developing local expertise.
Dr. Sodzi Sodzi-Tettey, the Chief Executive Officer of the NVI, emphasized the need for capital. "The issue of capital is crucial," he stated during a visit to Graphic's editor. "The two vaccine manufacturers and the institute are working with the required amount in excess of $100 million as a production cost." He also noted that since last August, the NVI organised an investment forum to gather resources. The institute has collaborated with Atlantic Life Sciences and secured a technology transfer agreement with PT Biopharma of Indonesia for tetanus-diphtheria vaccines, with local production targeted by 2027.
The success of this initiative depends on securing substantial investment and overcoming funding challenges. Development finance institutions have pledged billions to African countries, but conditionalities often hinder access for local manufacturers. The NVI aims to overcome these barriers to ensure Ghana's self-sufficiency in vaccine production. President Mahama has allocated $50 million in seed funding to the NVI to support manufacturing, research, and development, signalling strong governmental commitment. The global community recognizes Ghana's commitment, lending gravity to its aspirations for health independence.
Looking ahead, the NVI will focus on building robust manufacturing facilities that meet international Good Manufacturing Practice (GMP) standards. This will be critical for accessing further funding and ensuring the quality of locally produced vaccines. The institute's engagement with financial institutions and its proactive approach signal a determined effort to build a resilient local pharmaceutical industry. The target of 2030 represents a critical deadline for achieving this strategic objective.